Results for tag: "Lanadelumab"

Lanadelumab is a monoclonal antibody used to treat hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of swelling in the face, extremities, gastrointestinal tract, and airway. It is the first and only approved monoclonal antibody for the treatment of HAE. Lanadelumab works by blocking the activity of plasma kallikrein, an enzyme that is involved in the production of bradykinin, a molecule that causes swelling. By blocking the activity of plasma kallikrein, lanadelumab reduces the production of bradykinin and helps to prevent and reduce the severity of HAE attacks. Lanadelumab is approved for use in adults and adolescents aged 12 years and older. It is administered as a subcutaneous injection every two weeks. The most common side effects of lanadelumab include injection site reactions, upper respiratory tract infections, and headache. The lanadelumab market is a rapidly growing segment of the immune disorders drugs market. It is expected to benefit from the increasing prevalence of HAE and the growing demand for effective treatments. The market is also expected to benefit from the increasing number of clinical trials and the launch of new products. Some of the key players in the lanadelumab market include Shire, Sanofi, CSL Behring, and Grifols. Show Less Read more